Salute e Benessere

Expanding Capabilities for Clients: Olon to Open New High Potency API Suite in…

A GMP High Potency Active Pharmaceutical Ingredient (HPAPI) suite, currently under construction at the Olon USA site in Concord, Ohio, is the center of excellence for early development of APIs within the Olon Group. This adds to the significant commercial scale expertise and capabilities of the Segrate and Rodano sites near Milan, Italy, and it is part of an important growth of capabilities for handling HPAPI in the group where the company has invested overall around 40 million Euro in the...
Nasdaq GlobeNewswire
30/01/2024

Matisse Pharmaceuticals meets primary objectives in study with M6229 in…

In this first in human clinical study, performed at the intensive care unit (ICU) of the Amsterdam University Medical Center, in total 10 critically ill patients in ICU setting received a six-hour IV infusion of M6229. This study met its primary objectives, showing favorable safety and tolerability as well as close to dose-proportional pharmacokinetics of IV administered M6229 in critically ill patients with sepsis. In this first in human clinical study, performed at the intensive care unit...
PR Newswire
30/01/2024

Dr. Ranj Partners with Furniture Village to Reveal The 5 Best Ways to De-Stress…

5 ways to de-stress in the evening 5 ways to de-stress in the evening Dr. Ranj highlights 5 simple fixes to implement into your evening routine to increase relaxation. 1. Make the bedroom the ideal sleep haven Curating the perfect bed with a mattress, duvet and pillows that match your sleeping position isn't the only thing needed for a great night's sleep. You should also train your mind to ideally associate the bedroom with sleep. This might take a little adjusting – especially...
PR Newswire
30/01/2024

Results of the Phase III INSPIRE Study on Qilu Pharmaceutical's Iruplinalkib…

The INSPIRE study, a randomized, open-label, multicenter Phase III clinical trial compared the efficacy and safety of iruplinalkib against crizotinib in locally advanced or metastatic ALK-positive NSCLC patients who had not previously been treated with an ALK inhibitor. Key findings were presented at the 2023 World Conference on Lung Cancer. The INSPIRE study, a randomized, open-label, multicenter Phase III clinical trial compared the efficacy and safety of iruplinalkib against crizotinib in...
PR Newswire
30/01/2024

The Face of Nose Jobs: The Surgeon Who Has Performed Over 40,000 Rhinoplasties

Rhinoplasty, popularly known as the nose job, is a procedure that requires a delicate balance of artistry and surgical precision. Dr. Bizrah's proficiency, honed through years of experience and continuous education, enables him to sculpt and shape each patient's nose with astonishing precision, harmony and natural results. Rhinoplasty, popularly known as the nose job, is a procedure that requires a delicate balance of artistry and surgical precision. Dr. Bizrah's proficiency, honed through...
PR Newswire
30/01/2024

Suanfarma unifies its industrial brands in a rebranding initiative under…

In this manner, Suanfarma's sites, Cipan and Rovereto, are now acknowledged as part of a global and unified brand. Being collectively part of Suanfarma CDMO enhances visibility and flexibility in new projects, enabling the leveraging of synergies among the two factories in the group, in Portugal and Italy respectively. In this manner, Suanfarma's sites, Cipan and Rovereto, are now acknowledged as part of a global and unified brand. Being collectively part ofSuanfarma CDMO enhances visibility...
PR Newswire
30/01/2024

VENOMAID EXTENDS ITS SEED ROUND TO A TOTAL OF $ 1.8 M FOR AFFORDABLE AND RAPID…

Snakebite envenoming is a neglected tropical disease that kills >100,000 people and maims >400,000 people every year. According to the World Health Organisation, there are approximately 5.4 million snakebites each year, with up to 2.7 million resulting in severe envenoming. One of the main challenges in treating snakebites is the difficulty in identifying the type of snake that bit the victim. This is important because different types of snakes have different venom, and the appropriate…
PR Newswire
30/01/2024

Implantica's RefluxStop™ procedure now available in Norway

Dr. Gaupset says, "We believe RefluxStop™ has the potential to offer a superior surgical treatment against GERD/reflux, with fewer side effects compared to current alternatives. RefluxStop treats acid reflux without encircling the food passageway. We look forward to evaluating RefluxStop's long-term efficacy in the Norwegian registry study, as part of the wider pan-European study." Dr. Gaupset says, "We believe RefluxStop™ has the potential to offer a superior surgical treatment…
PR Newswire
30/01/2024

SciBase initiates collaboration with Inderes for commissioned research

The main purpose of the collaboration is to: The main purpose of the collaboration is to: For additional information, please contact: Pia Renaudin, VD, tel. +46732069802, e-mail:pia.renaudin@scibase.com Michael Colerus, CFO, tel. +46703413472, e-mail:Michael.colerus@scibase.com Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: ca@vatorsec.se About SciBase SciBase is a global medical technology company, specializing in early detection...
PR Newswire
30/01/2024

PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific…

Gdańsk, Poland – 30 January 2024– PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune diseases, announced that Prof. Piotr Trzonkowski, CEO, has co-authored a peer-reviewed article in Frontiers in Immunology, the world's fifth most-cited immunology journal, laying out the decades of scientific progress underlying the company's portfolio of ground-breaking clinical-stage therapies for...
Nasdaq GlobeNewswire
30/01/2024

BioSenic patent granted in Canada for broader protection of ATO therapeutic…

PRESS RELEASE – INSIDE INFORMATION BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration.Enriched IP portfolio protects arsenic trioxide (ATO) use combined with copper ions delivery, which has demonstrated increased therapeutic potential for indications ranging from immune to cancer and infectious diseases. ...
Nasdaq GlobeNewswire
30/01/2024

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial…

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0.14% or 0.29%) demonstrated excellent safety and tolerability Low dose (0.14%) showed significant improvement over active control in clinical and mycological outcome at day 29 1 Liège, Belgium – 30 January 2024, 07:00 AM CET – Regulated information – Inside information...
Nasdaq GlobeNewswire
30/01/2024

INTERIM REPORT FOR Q1 2023/24

In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT, combined with pulmonology growing 18%. “I am pleased with the performance within the first quarter of the year, showcasing our continued commitment to delivering strong profitable growth. With 25% growth in Endoscopy Solutions, an increased profitability level and a...
Nasdaq GlobeNewswire
30/01/2024

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related…

PARIS and CAMBRIDGE, Mass., Jan.29, 2024(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext : NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a...
Nasdaq GlobeNewswire
29/01/2024

INSIGHTEC MR-GUIDED FOCUSED ULTRASOUND TECHNOLOGY RECOMMENDED FOR NATIONAL…

Released to the public on the public on December 18, 2023, the ZIN recommendation concludes that MRgFUS (also called high-intensity focused ultrasound, or HIFU) which was pioneered by Insightec, is an effective treatment for patients with moderate to severe medication-refractory essential tremor who are not suitable for deep brain stimulation. It also concludes that these patients should therefore be included in the national basic health insurance package, which would guarantee patient access to…
PR Newswire
29/01/2024

Electrophysiology Market Worth $15.1 Billion | MarketsandMarkets™

Browse in-depth TOC on "Electrophysiology Market" Browse in-depth TOC on "Electrophysiology Market" 186 - Tables 39 - Figures 238 - Pages Electrophysiology Market Scope: The Electrophysiology market by Product is segmented into Electrophysiology ablation catheters, electrophysiology laboratory devices, electrophysiology diagnostic catheters, electrophysiology access devices, and other devices. The electrophysiology laboratory devices accounted for the largest segment in...
PR Newswire
29/01/2024

Mosquito Repellent Clothing Market Size to Grow USD 520.8 Million by 2030 at a…

Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-24W7142/Global_Mosquito_Repellent_Clothing_Market Claim Your Free Sample Now:https://reports.valuates.com/request/sample/QYRE-Auto-24W7142/Global_Mosquito_Repellent_Clothing_Market Major Factors Driving the Growth of Mosquito Repellent Clothing Market : The market for mosquito-repellent clothing is expanding rapidly due to a number of variables coming together. The need for novel solutions, such as...
PR Newswire
29/01/2024

Fluorine-Free Water Repellent Market Size to Grow USD 538 Million by 2029 at a…

Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-22U12850/Global_Fluorine_free_Water_Repellent Claim Your Free Sample Now:https://reports.valuates.com/request/sample/QYRE-Auto-22U12850/Global_Fluorine_free_Water_Repellent Major Factors Driving the Growth of Fluorine-free Water Repellent Market : The market for fluorine-free water repellent is expanding significantly due to a combination of growing health and safety awareness, regulatory changes,...
PR Newswire
29/01/2024

Trading by management and close relations of management

January 29, 2024Company announcement No. 04 Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B.Please read the full announcement in PDF...
Nasdaq GlobeNewswire
29/01/2024

Mindray Showcased Latest Innovations in Smart Hospital Solutions at Arab Health…

Mindray's Smart Hospital contributes to creating a medical ecosystem where medical devices are integrated into clinical scenarios, enabling smooth data exchange across departments, hospitals, and regions. It provides a patient-focused system for medical professionals, ensuring better patient safety and optimized hospital workflow. Mindray's Smart Hospital contributes to creating a medical ecosystem where medical devices are integrated into clinical scenarios, enabling smooth data exchange...
PR Newswire
29/01/2024

Orion publishes Financial Statement Release for 2023 and holds a webcast on 13…

ORION CORPORATIONPRESS RELEASE29 January 2024 at 15.00 EET Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024 Orion will publish Financial Statement Release for 2023 on Tuesday, 13 February 2024 at approximately 12.00 noon EET. The release and related presentation material will be available on the company's website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and a conference call for analysts,...
Nasdaq GlobeNewswire
29/01/2024

ClariMed Announces Liz Wellwood as New Head of Quality and Launches…

ClariMed is also introducing a suite of quality assurance services that address each stage of medical device development, meeting stringent quality standards while enhancing usability and user experience. These include: ClariMed is also introducing a suite of quality assurance services that address each stage of medical device development, meeting stringent quality standards while enhancing usability and user experience. These include: Liz Wellwoodcommented, "I'm eager to grow ClariMed's...
PR Newswire
29/01/2024

Major shareholder announcement

Major shareholder announcementJanuary 29, 2024Company announcement No. 03 On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of a statutory merger of the two companies (the "Combination"), was successfully completed. Reference is made to Novozymes' company announcement no. 2 of January 29, 2024.Pursuant to Section 30...
Nasdaq GlobeNewswire
29/01/2024

BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT

About BioVaxys Technology Corp. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( www.biovaxys.com ), is a biopharmaceuticals company registered inBritish Columbiadedicated to improving patient lives with immunotherapeutics based on its HapTenix© 'neoantigen' tumor cell construct platform. The Company's clinical stage pipeline includes BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'platform, which is planned to enter Phase I inSpain...
PR Newswire
29/01/2024
Altri  Comunicati